Bortezomib for the treatment in acute immune thrombotic thrombocytopenic purpura (TTP) and elective therapy to prevent immune TTP relapse in patients who are refractory or intolerant to rituximab (all ages)

Document first published:
Page updated:
Topic:
Publication type:

NHS England will not routinely commission bortezomib for the treatment in acute immune thrombotic thrombocytopenic purpura (TTP) and elective therapy to prevent immune TTP relapse in patients who are refractory or intolerant to rituximab in accordance with the criteria outlined in this document.

Document

Clinical commissioning policy: bortezomib for the treatment in acute immune thrombotic thrombocytopenic purpura (TTP) and elective therapy to prevent immune TTP relapse in patients who are refractory or intolerant to rituximab (all ages)

Clinical commissioning policy: bortezomib for the treatment in acute immune thrombotic thrombocytopenic purpura (TTP) and elective therapy to prevent immune TTP relapse in patients who are refractory or intolerant to rituximab (all ages)

  • PDF
  • 150 KB
  • 5 pages

Summary

Published 19 August 2025.

Document

Clinical Priorities Advisory Group summary report: bortezomib for the treatment in acute immune thrombotic thrombocytopenic purpura

Clinical Priorities Advisory Group summary report: bortezomib for the treatment in acute immune thrombotic thrombocytopenic purpura

  • PDF
  • 278 KB
  • 11 pages

Summary

Published 19 August 2025.

Document

Clinical panel report: bortezomib for acute thrombotic thrombocytopenic purpura

Clinical panel report: bortezomib for acute thrombotic thrombocytopenic purpura

  • PDF
  • 131 KB
  • 2 pages

Summary

Published 19 August 2025.

Document

NHS England evidence review: bortezomib for acute immune thrombotic thrombocytopenic purpura

NHS England evidence review: bortezomib for acute immune thrombotic thrombocytopenic purpura

  • PDF
  • 315 KB
  • 30 pages

Summary

Published 19 August 2025.

Document

NHS England evidence review: bortezomib for prevention of acute thrombotic thrombocytopenic purpura

NHS England evidence review: bortezomib for prevention of acute thrombotic thrombocytopenic purpura

  • PDF
  • 238 KB
  • 26 pages

Summary

Published 19 August 2025.

Document

Engagement report: bortezomib for immune thrombotic thrombocytopenic purpura

Engagement report: bortezomib for immune thrombotic thrombocytopenic purpura

  • PDF
  • 181 KB
  • 2 pages

Summary

Published 19 August 2025.

Document

Equality and health inequalities impact assessment: bortezomib for immune thrombotic thrombocytopenic purpura

Equality and health inequalities impact assessment: bortezomib for immune thrombotic thrombocytopenic purpura

  • PDF
  • 235 KB
  • 8 pages

Summary

Published 19 August 2025.